Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00683280 · ClinicalTrials.gov registry record · NA

Contingency Management and Pharmacotherapy for Smoking Cessation

A NA study of Cigarette Smoking, sponsored by UConn Health.

Completed
Registry status
NA
Development phase
59
Enrollment target
1
Study location

NCT00683280: Completed NA study of Cigarette Smoking, sponsored by UConn Health.

NCT00683280 is a NA study of Cigarette Smoking that has completed, run by UConn Health. The registered enrollment target is 59 participants, below the 175-participant average among 45 other Cigarette Smoking trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00683280, a NA study of Cigarette Smoking, has completed, sponsored by UConn Health.

COMPLETED
Registry status
NA
Development phase
59 participants
Enrollment target
1
Study location

Study Summary

In total, 70 smokers will be randomized to: standard of care smoking cessation medication varenicline alone (an FDA-approved smoking cessation medication) or varenicline plus contingency management (CM) (a behavioral procedure with rewards for target behaviors, like smoking abstinence). Patients in both conditions will receive varenicline for 12 weeks with standard smoking cessation therapy and regular breath and urine sample monitoring for smoking. Patients assigned to CM will earn chances to win prizes for each breath sample that tests negative for smoking, and urine samples that test negative for smoking will result in even greater chances for prizes. More CM patients are expected to achieve and maintain abstinence than patients receiving varenicline alone.

Conditions Studied

Interventions

  • OTHER Standard of Care
  • BEHAVIORAL contingency management

Study Locations (1)

Connecticut

  • University of Connecticut Health Center - Farmington

Trial Details

FieldValue
Enrollment Target 59 participants
Start Date 2008-05
Est. Completion 2010-08
Phase NA
UConn Health

178 total trials

What the finished NCT00683280 record still lists

NCT00683280 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 175-participant average among 45 other Cigarette Smoking trials with a reported enrollment target (66% lower).

The record links to 1 condition, with Cigarette Smoking appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.

NCT00683280 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT00683280 about?

NCT00683280 is a clinical study titled "Contingency Management and Pharmacotherapy for Smoking Cessation". In total, 70 smokers will be randomized to: standard of care smoking cessation medication varenicline alone (an FDA-approved smoking cessation medication) or varenicline plus contingency management (CM) (a behavioral procedure with rewards for target behaviors, like smoking abstinence). Patients in ...

What is the current status of trial NCT00683280?

This trial is currently completed. It is a NA study. The enrollment target is 59 participants. The study started on 2008-05. Estimated completion is 2010-08.

What conditions does trial NCT00683280 study?

This clinical trial studies the following conditions: Cigarette Smoking.

What interventions are being tested in trial NCT00683280?

The interventions under investigation include: Standard of Care (OTHER), contingency management (BEHAVIORAL).

Who is sponsoring clinical trial NCT00683280?

This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00683280 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cigarette Smoking

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00683280's enrollment target sits among peer trials

59 31st of 45 higher than 15 of 45 other Cigarette Smoking trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cigarette Smoking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03801083 · 59 participants · Phase 2

    Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers

  • NCT04332367 · 59 participants · Phase 2

    Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

  • NCT05489575 · 59 participants · NA

    CPAP for the Treatment of Supine Hypertension

  • NCT06721689 · 59 participants · Phase 1

    PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00683280, the US trial registry maintained by the National Library of Medicine. NCT00683280 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.